<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101127833</journal-id>
<journal-id journal-id-type="pubmed-jr-id">27020</journal-id>
<journal-id journal-id-type="nlm-ta">Expert Opin Ther Targets</journal-id>
<journal-id journal-id-type="iso-abbrev">Expert Opin. Ther. Targets</journal-id>
<journal-title-group>
<journal-title>Expert opinion on therapeutic targets</journal-title>
</journal-title-group>
<issn pub-type="ppub">1472-8222</issn>
<issn pub-type="epub">1744-7631</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29667529</article-id>
<article-id pub-id-type="pmc">7017752</article-id>
<article-id pub-id-type="doi">10.1080/14728222.2018.1465931</article-id>
<article-id pub-id-type="manuscript">NIHMS1065758</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Emerging therapeutic targets for neurofibromatosis type 1 (NF1)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Walker</surname>
<given-names>James A.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Upadhyaya</surname>
<given-names>Meena</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label>Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA</aff>
<aff id="A2"><label>b</label>Division of Cancer and Genetics, Cardiff University, Cardiff, UK</aff>
<pub-date pub-type="nihms-submitted">
<day>3</day>
<month>1</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>07</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>13</day>
<month>2</month>
<year>2020</year>
</pub-date>
<volume>22</volume>
<issue>5</issue>
<fpage>419</fpage>
<lpage>437</lpage>
<!--elocation-id from pubmed: 10.1080/14728222.2018.1465931-->
<abstract id="ABS1">
<sec id="S1">
<title>Introduction</title>
<p id="P1">Neurofibromatosis type 1 (NF1) is an autosomal dominantly inherited tumor predisposition syndrome with an incidence of one in 3000â€“4000 individuals with no currently effective therapies. The <italic>NF1</italic> gene on chromosome 17 encodes neurofibromin, which functions as a negative regulator of RAS. NF1 is a chronic multi-system disorder affecting many different tissues. Due to cell-specific complexities of RAS signaling, therapeutic approaches for NF1 will likely have to focus on a particular tissue and manifestation of the disease.</p>
</sec>
<sec id="S2">
<title>Areas covered</title>
<p id="P2">In this review, we discuss the multi-system nature of NF1 and the signaling pathways affected due to deficiency of neurofibromin. We explore the cell/tissue-specific molecular and cellular consequences of aberrant RAS signaling in NF1 and speculate on their potential as therapeutic targets for the disease. We discuss recent genomic, transcriptomic and proteomic studies combined with molecular, cellular and biochemical analyses which have identified several targets for specific NF1 manifestations. We also consider the possibility of patient-specific gene therapy approaches to tackle NF1.</p>
</sec>
<sec id="S3">
<title>Expert opinion</title>
<p id="P3">The emergence of NF1 genotype-phenotype correlations, characterization of cell-specific signaling pathways affected in NF1, identification of novel biomarkers, and the development of sophisticated animal models accurately reflecting human pathology will continue to provide opportunities to develop therapeutic approaches to combat this multi-system disorder.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Neurofibromas</kwd>
<kwd>neurofibromatosis type 1</kwd>
<kwd>peripheral nerve sheath tumors</kwd>
<kwd>RAS-MEK-ERK signaling</kwd>
<kwd>RASopathies</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>